Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Renalytix Collaborates With ADA To Improve Early Detection Of Kidney Disease

Executive Summary

The American Diabetes Association and Renalytix will develop a comprehensive interprofessional risk-informed Diabetes Kidney Care Pathway and Model for optimal clinical treatment and risk reduction that can be applied nationally.

You may also be interested in...



Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.

JPM 2022: Abiomed, Penumbra, Renalityx

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the fourth day of the meeting.

Renalytix AI And AstraZeneca Collaborate To Improve Chronic Kidney Disease Outcomes

The companies will launch "precision medicine strategies" for chronic disease that use Renalytix' AI-enabled IVDs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT144926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel